Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVA6103 in FAP-positive Solid Tumors
NCT07454642Phase 1Recruiting
- Sponsor
- Avacta
- Start
- Mar 2026
- Primary completion
- Jan 2029
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of AVA6103 in vulvar adenocarcinoma, pancreatic ductal adenocarcinoma (PDAC), gastric adenocarcinoma and 6 more (3 arms), sponsored by Avacta. Primary endpoints: Adverse Events and Dose-Limiting Toxicities at 28 days. Started Mar 2026; status: recruiting.
02
Drugs
AVA6103
03
Conditions
vulvar adenocarcinomapancreatic ductal adenocarcinoma (PDAC)gastric adenocarcinomagastroesophageal junction adenocarcinomacervical adenocarcinoma
Beyond the preview
Go deeper on NCT07454642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454642.